these r & d projects include certain products that we have dubbed our `` significant seven `` , which are products recently launched or expected to launch in the near term pending completion of testing and receiving fda approval . our significant seven are : ( i ) vyzulta ( bausch + lomb ) , ( ii ) siliq ( psoriasis ) , ( iii ) jemdel ( psoriasis ) , ( iv ) lumify ( bausch + lomb ) , ( v ) duobrii ( psoriasis ) , ( vi ) relistor ® ( gi ) and ( vii ) the bausch + lomb ultra ® product lines ( bausch + lomb ) . as outlined later in the discussion of our transformation , although the 2017 revenues associated with our significant seven are not material , we believe the prospects for this group of products over the next five years are substantial . history following the company 's ( then named biovail corporation ) acquisition of valeant pharmaceuticals international on september 28 , 2010 , we supplemented our internal r & d efforts with strategic acquisitions to expand our portfolio offerings and geographic footprint . in 2013 , we acquired bausch & lomb holdings incorporated ( “ b & l ” ) ( the “ b & l acquisition ” ) , a global eye-health company that focuses on developing , manufacturing and marketing eye-health products , including contact lenses , contact lens care solutions , ophthalmic pharmaceuticals and ophthalmic surgical products . in 2015 , we acquired salix pharmaceuticals , ltd. ( “ salix ” ) ( the “ salix acquisition ” ) , a specialty pharmaceutical company dedicated to developing and commercializing prescription drugs and medical devices used in treatment of a variety of gi disorders with a portfolio of over 20 marketed products , including xifaxan ® , uceris ® , apriso ® , glumetza ® and relistor ® . in 2015 , we acquired the exclusive licensing rights to develop and commercialize brodalumab , an il-17 receptor monoclonal antibody for patients with moderate-to-severe 40 plaque psoriasis for which , following internal development work , on february 15 , 2017 , we received approval from the u.s. food and drug administration ( “ fda ” ) . on july 27 , 2017 , we launched this product in the u.s. , marketed as siliq . we believe the investments we have made in b & l , salix , brodalumab and other acquisitions , as well as our ongoing investments in our internal r & d efforts , are helping us to capitalize on the core geographies and therapeutic classes that have the potential for strong operating margins and offer attractive growth opportunities . while business development through acquisitions may continue to be a component of our long-term strategy , we have made minimal acquisitions since 2015 and expect the volume and size of acquisitions to be low in the foreseeable future . see note 3 , `` acquisitions `` to our audited consolidated financial statements for additional details regarding acquisitions . our transformation prior to 2016 , we had completed a series of mergers and acquisitions which were in-line with the company 's previous strategy for growth . however , in response to changing business dynamics within our company , we recognized the need to change our focus in order to build a world-class health care organization . in 2016 , we retained a new executive team which immediately implemented a multi-year plan to stabilize , turnaround and transform the company . stabilize in 2016 the new executive team : ( i ) identified and retained a new leadership team , ( ii ) enhanced the company 's focus on core assets , which enabled the company to recruit and retain stronger talent for its sales initiatives and ( iii ) realigned the company 's operations to improve transparency and operational efficiency and better support the company 's sales force . once in place , the new leadership team began executing on the turnaround phase of the multi-year action plan and delivering on commitments to narrow the company 's activities to our core businesses where we believe we have an existing and sustainable competitive edge and to identify opportunities to improve operational efficiencies and our capital structure . turnaround throughout 2017 and into 2018 , the company continues to execute on its commitments to stabilize and turnaround the company . during this time , we : ( i ) have better defined our core businesses , ( ii ) made measurable progress in improving our capital structure and ( iii ) have been aggressively addressing and resolving certain legacy matters to eliminate disruptions to our operations . focus on core businesses we have found and continue to believe that there is significant opportunity in the : ( i ) eye-health , ( ii ) gi and ( iii ) dermatology businesses . we believe that our existing portfolio , commercial footprint and pipeline of product development projects position us to successfully compete in these markets and provide us with the greatest opportunity to build value for our shareholders . we identify these businesses as “ core ” , meaning that we believe we are best positioned to grow and develop them . by narrowing our focus , we have the opportunity to reduce complexity in our operations and maximize the value of our core businesses . in order to focus our efforts , we performed a review of our portfolio of assets within these core businesses to identify those products where we believe we have , and can maintain , a competitive advantage and we continue to define and shape our operations and business strategies around these assets . once we committed to our core businesses , we began analyzing what to do with those business units and assets that fall outside our definition of “ core ” . story_separator_special_tag the bausch + lomb ultra ® for presbyopia lens was developed using the proprietary moistureseal ® technology . in addition , the bausch + lomb ultra ® for presbyopia lens integrates a 3 zone progressive design for near , intermediate and distance vision . we launched expanded parameters of this product throughout 2017. bausch + lomb - bausch + lomb scleralfil ® solution is a novel contact lens care solution that makes use of a preservative free buffered saline solution for use with the insertion of scleral lenses and was launched in 2017. bausch + lomb - bausch + lomb renu ® advanced formula multi-purpose solution is a novel soft and silicone hydrogel contact lens solution that makes use of three disinfectants and two moisture agents and was launched in may 2017. bausch + lomb - we are developing a new ophthalmic viscosurgical device product , with a formulation to protect corneal endothelium during phaco emulsification process during a cataract surgery and to help chamber maintenance and 44 lubrication during interocular lens delivery . the planned investigative device exemption ( “ ide ” ) study is scheduled to begin in the first half of 2018. dermatology - traser is an energy-based platform device with significant versatility and power capabilities to address various dermatological conditions , including vascular and pigmented lesions . we are planning to launch this product in the second half of 2019 as part of our solta business . bausch + lomb - loteprednol gel 0.38 % is a new formulation for the treatment of post-operative ocular inflammation and pain with lower drug concentration and less frequent dosing . we have completed phase iii testing and expect to file an nda for this product in the first half of 2018. bausch + lomb - envista ® trifocal intraocular lens is an innovative lens design and expect to initiate an ide study for this product in 2018. improve capital structure by executing our strategies during 2017 , we have made measurable progress in improving our capital structure through debt reduction and extending debt maturities . using cash generated from operations , the net cash proceeds from divestitures of non-core assets and cash generated from tighter working capital management , we repaid ( net of additional borrowings ) over $ 5,800 million of long-term debt during 2017 and 2016 , in the aggregate . in january 2018 , we also made a $ 200 million payment of our series f tranche b term loan facility , which we directed to be applied to satisfy ( in part ) payment of the expected $ 206 million consolidated excess cash flow payment for the year 2017. under our senior secured credit facilities , subject to certain exceptions and reductions , we are required to make mandatory annual principal prepayments equal to 50 % of the company 's consolidated excess cash flow , if any , as defined in its credit agreement . we accessed the credit markets in march , october , november and december of 2017 , and completed a series of refinancing transactions to improve our capital structure , whereby we extended the maturities of certain debt obligations originally scheduled to mature in the years 2018 through 2022 out to march 2022 through december 2025. furthermore , we extended $ 1,190 million of commitments under our revolving credit facility , originally set to expire in april 2018 , out to april 2020. as a result of these debt repayments and refinancing transactions , we have eliminated all mandatory scheduled principal long-term debt repayments through march 2020 , providing us with additional liquidity and greater flexibility to execute our business plans . our reduced debt levels and improved debt portfolio will translate to lower payments of principal over the next three years , which , in turn , will permit more cash flow to be directed toward developing our core assets and repaying additional debt amounts . divestitures - during 2017 , we divested businesses and assets not aligned with our core business objectives which simplified our operating model and generated over $ 3,200 million of net cash proceeds that we used to improve our capital structure . the most significant of these divestitures were as follows . in march 2017 , we completed the sale of the cerave ® , acnefree and ambi ® skincare brands to a global beauty company for $ 1,300 million in cash ( the “ skincare sale ” ) . aggregate annual revenue associated with these skincare brands was less than $ 200 million . over the course of the first half of 2017 , using the net proceeds from the skincare sale and the divestiture of a manufacturing facility in brazil , the company repaid $ 1,306 million , of its series f tranche b term loan facility . in june 2017 , we completed the sale of our equity interests in dendreon pharmaceuticals llc ( formerly dendreon pharmaceuticals , inc. ) ( “ dendreon ” ) for $ 845 million in cash ( the “ dendreon sale ” ) , as adjusted through december 31 , 2017. dendreon 's only commercialized product , provenge ® , is an autologous cellular immunotherapy ( vaccine ) for prostate cancer treatment approved by the fda in april 2010. revenues from provenge ® were $ 164 million , $ 303 million and $ 250 million in 2017 , 2016 and 2015 , respectively . with this sale completed , we have exited the oncology business , which was not core to our objectives . on july 3 , 2017 , using the net proceeds from the dendreon sale , the company repaid $ 811 million of its series f tranche b term loan facility . in september 2017 , we completed the sale of our australian-based inova pharmaceuticals ( “ inova ” ) business for $ 938 million in cash ( the “ inova sale ” ) , as adjusted , and subject to the finalization of

loss on extinguishment of debt of $ 122 million . net income attributable to valeant pharmaceuticals international , inc. for 2017 was $ 2,404 million as compared to net loss attributable to valeant pharmaceuticals international , inc. for 2016 of $ 2,409 million , an increase of $ 4,813 million . the increase in net income attributable to valeant pharmaceuticals international , inc. was primarily due to : ( i ) the increase in the benefit from income taxes of $ 4,118 million which in 2017 includes non-cash income tax benefits related to the company 's internal corporate restructuring and the accounting for the tax act and ( ii ) the decrease in loss before ( benefit from ) provision for income taxes of $ 694 million previously described . see note 18 , `` income taxes '' to our audited consolidated financial statements for further details . 57 summary of 2016 compared with 2015 our revenue for 2016 and 2015 was $ 9,674 million and $ 10,447 million , respectively , a decrease of $ 773 million , or 7 % . the decrease was primarily driven by the decreases in the branded rx segment and u.s. diversified products segment revenues . the changes in our segment revenues and segment profits are discussed in detail in the subsequent section titled `` reportable segment revenues and profits '' . operating loss for 2016 was $ 566 million as compared to operating income for 2015 of $ 1,527 million , a decrease of $ 2,093 million . our 2016 operating loss compared to our 2015 operating income reflects , among other factors : a decrease in contribution of $ 796 million . the decrease is primarily driven by : ( i ) lower average realized pricing and ( ii ) lower volumes . the decreases in contribution were partially offset by the incremental contributions from the salix acquisition , the acquisition of amoun pharmaceutical company s.a.e .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```loss on extinguishment of debt of $ 122 million . net income attributable to valeant pharmaceuticals international , inc. for 2017 was $ 2,404 million as compared to net loss attributable to valeant pharmaceuticals international , inc. for 2016 of $ 2,409 million , an increase of $ 4,813 million . the increase in net income attributable to valeant pharmaceuticals international , inc. was primarily due to : ( i ) the increase in the benefit from income taxes of $ 4,118 million which in 2017 includes non-cash income tax benefits related to the company 's internal corporate restructuring and the accounting for the tax act and ( ii ) the decrease in loss before ( benefit from ) provision for income taxes of $ 694 million previously described . see note 18 , `` income taxes '' to our audited consolidated financial statements for further details . 57 summary of 2016 compared with 2015 our revenue for 2016 and 2015 was $ 9,674 million and $ 10,447 million , respectively , a decrease of $ 773 million , or 7 % . the decrease was primarily driven by the decreases in the branded rx segment and u.s. diversified products segment revenues . the changes in our segment revenues and segment profits are discussed in detail in the subsequent section titled `` reportable segment revenues and profits '' . operating loss for 2016 was $ 566 million as compared to operating income for 2015 of $ 1,527 million , a decrease of $ 2,093 million . our 2016 operating loss compared to our 2015 operating income reflects , among other factors : a decrease in contribution of $ 796 million . the decrease is primarily driven by : ( i ) lower average realized pricing and ( ii ) lower volumes . the decreases in contribution were partially offset by the incremental contributions from the salix acquisition , the acquisition of amoun pharmaceutical company s.a.e .
```    
 Suspicious Activity Report : these r & d projects include certain products that we have dubbed our `` significant seven `` , which are products recently launched or expected to launch in the near term pending completion of testing and receiving fda approval . our significant seven are : ( i ) vyzulta ( bausch + lomb ) , ( ii ) siliq ( psoriasis ) , ( iii ) jemdel ( psoriasis ) , ( iv ) lumify ( bausch + lomb ) , ( v ) duobrii ( psoriasis ) , ( vi ) relistor ® ( gi ) and ( vii ) the bausch + lomb ultra ® product lines ( bausch + lomb ) . as outlined later in the discussion of our transformation , although the 2017 revenues associated with our significant seven are not material , we believe the prospects for this group of products over the next five years are substantial . history following the company 's ( then named biovail corporation ) acquisition of valeant pharmaceuticals international on september 28 , 2010 , we supplemented our internal r & d efforts with strategic acquisitions to expand our portfolio offerings and geographic footprint . in 2013 , we acquired bausch & lomb holdings incorporated ( “ b & l ” ) ( the “ b & l acquisition ” ) , a global eye-health company that focuses on developing , manufacturing and marketing eye-health products , including contact lenses , contact lens care solutions , ophthalmic pharmaceuticals and ophthalmic surgical products . in 2015 , we acquired salix pharmaceuticals , ltd. ( “ salix ” ) ( the “ salix acquisition ” ) , a specialty pharmaceutical company dedicated to developing and commercializing prescription drugs and medical devices used in treatment of a variety of gi disorders with a portfolio of over 20 marketed products , including xifaxan ® , uceris ® , apriso ® , glumetza ® and relistor ® . in 2015 , we acquired the exclusive licensing rights to develop and commercialize brodalumab , an il-17 receptor monoclonal antibody for patients with moderate-to-severe 40 plaque psoriasis for which , following internal development work , on february 15 , 2017 , we received approval from the u.s. food and drug administration ( “ fda ” ) . on july 27 , 2017 , we launched this product in the u.s. , marketed as siliq . we believe the investments we have made in b & l , salix , brodalumab and other acquisitions , as well as our ongoing investments in our internal r & d efforts , are helping us to capitalize on the core geographies and therapeutic classes that have the potential for strong operating margins and offer attractive growth opportunities . while business development through acquisitions may continue to be a component of our long-term strategy , we have made minimal acquisitions since 2015 and expect the volume and size of acquisitions to be low in the foreseeable future . see note 3 , `` acquisitions `` to our audited consolidated financial statements for additional details regarding acquisitions . our transformation prior to 2016 , we had completed a series of mergers and acquisitions which were in-line with the company 's previous strategy for growth . however , in response to changing business dynamics within our company , we recognized the need to change our focus in order to build a world-class health care organization . in 2016 , we retained a new executive team which immediately implemented a multi-year plan to stabilize , turnaround and transform the company . stabilize in 2016 the new executive team : ( i ) identified and retained a new leadership team , ( ii ) enhanced the company 's focus on core assets , which enabled the company to recruit and retain stronger talent for its sales initiatives and ( iii ) realigned the company 's operations to improve transparency and operational efficiency and better support the company 's sales force . once in place , the new leadership team began executing on the turnaround phase of the multi-year action plan and delivering on commitments to narrow the company 's activities to our core businesses where we believe we have an existing and sustainable competitive edge and to identify opportunities to improve operational efficiencies and our capital structure . turnaround throughout 2017 and into 2018 , the company continues to execute on its commitments to stabilize and turnaround the company . during this time , we : ( i ) have better defined our core businesses , ( ii ) made measurable progress in improving our capital structure and ( iii ) have been aggressively addressing and resolving certain legacy matters to eliminate disruptions to our operations . focus on core businesses we have found and continue to believe that there is significant opportunity in the : ( i ) eye-health , ( ii ) gi and ( iii ) dermatology businesses . we believe that our existing portfolio , commercial footprint and pipeline of product development projects position us to successfully compete in these markets and provide us with the greatest opportunity to build value for our shareholders . we identify these businesses as “ core ” , meaning that we believe we are best positioned to grow and develop them . by narrowing our focus , we have the opportunity to reduce complexity in our operations and maximize the value of our core businesses . in order to focus our efforts , we performed a review of our portfolio of assets within these core businesses to identify those products where we believe we have , and can maintain , a competitive advantage and we continue to define and shape our operations and business strategies around these assets . once we committed to our core businesses , we began analyzing what to do with those business units and assets that fall outside our definition of “ core ” . story_separator_special_tag the bausch + lomb ultra ® for presbyopia lens was developed using the proprietary moistureseal ® technology . in addition , the bausch + lomb ultra ® for presbyopia lens integrates a 3 zone progressive design for near , intermediate and distance vision . we launched expanded parameters of this product throughout 2017. bausch + lomb - bausch + lomb scleralfil ® solution is a novel contact lens care solution that makes use of a preservative free buffered saline solution for use with the insertion of scleral lenses and was launched in 2017. bausch + lomb - bausch + lomb renu ® advanced formula multi-purpose solution is a novel soft and silicone hydrogel contact lens solution that makes use of three disinfectants and two moisture agents and was launched in may 2017. bausch + lomb - we are developing a new ophthalmic viscosurgical device product , with a formulation to protect corneal endothelium during phaco emulsification process during a cataract surgery and to help chamber maintenance and 44 lubrication during interocular lens delivery . the planned investigative device exemption ( “ ide ” ) study is scheduled to begin in the first half of 2018. dermatology - traser is an energy-based platform device with significant versatility and power capabilities to address various dermatological conditions , including vascular and pigmented lesions . we are planning to launch this product in the second half of 2019 as part of our solta business . bausch + lomb - loteprednol gel 0.38 % is a new formulation for the treatment of post-operative ocular inflammation and pain with lower drug concentration and less frequent dosing . we have completed phase iii testing and expect to file an nda for this product in the first half of 2018. bausch + lomb - envista ® trifocal intraocular lens is an innovative lens design and expect to initiate an ide study for this product in 2018. improve capital structure by executing our strategies during 2017 , we have made measurable progress in improving our capital structure through debt reduction and extending debt maturities . using cash generated from operations , the net cash proceeds from divestitures of non-core assets and cash generated from tighter working capital management , we repaid ( net of additional borrowings ) over $ 5,800 million of long-term debt during 2017 and 2016 , in the aggregate . in january 2018 , we also made a $ 200 million payment of our series f tranche b term loan facility , which we directed to be applied to satisfy ( in part ) payment of the expected $ 206 million consolidated excess cash flow payment for the year 2017. under our senior secured credit facilities , subject to certain exceptions and reductions , we are required to make mandatory annual principal prepayments equal to 50 % of the company 's consolidated excess cash flow , if any , as defined in its credit agreement . we accessed the credit markets in march , october , november and december of 2017 , and completed a series of refinancing transactions to improve our capital structure , whereby we extended the maturities of certain debt obligations originally scheduled to mature in the years 2018 through 2022 out to march 2022 through december 2025. furthermore , we extended $ 1,190 million of commitments under our revolving credit facility , originally set to expire in april 2018 , out to april 2020. as a result of these debt repayments and refinancing transactions , we have eliminated all mandatory scheduled principal long-term debt repayments through march 2020 , providing us with additional liquidity and greater flexibility to execute our business plans . our reduced debt levels and improved debt portfolio will translate to lower payments of principal over the next three years , which , in turn , will permit more cash flow to be directed toward developing our core assets and repaying additional debt amounts . divestitures - during 2017 , we divested businesses and assets not aligned with our core business objectives which simplified our operating model and generated over $ 3,200 million of net cash proceeds that we used to improve our capital structure . the most significant of these divestitures were as follows . in march 2017 , we completed the sale of the cerave ® , acnefree and ambi ® skincare brands to a global beauty company for $ 1,300 million in cash ( the “ skincare sale ” ) . aggregate annual revenue associated with these skincare brands was less than $ 200 million . over the course of the first half of 2017 , using the net proceeds from the skincare sale and the divestiture of a manufacturing facility in brazil , the company repaid $ 1,306 million , of its series f tranche b term loan facility . in june 2017 , we completed the sale of our equity interests in dendreon pharmaceuticals llc ( formerly dendreon pharmaceuticals , inc. ) ( “ dendreon ” ) for $ 845 million in cash ( the “ dendreon sale ” ) , as adjusted through december 31 , 2017. dendreon 's only commercialized product , provenge ® , is an autologous cellular immunotherapy ( vaccine ) for prostate cancer treatment approved by the fda in april 2010. revenues from provenge ® were $ 164 million , $ 303 million and $ 250 million in 2017 , 2016 and 2015 , respectively . with this sale completed , we have exited the oncology business , which was not core to our objectives . on july 3 , 2017 , using the net proceeds from the dendreon sale , the company repaid $ 811 million of its series f tranche b term loan facility . in september 2017 , we completed the sale of our australian-based inova pharmaceuticals ( “ inova ” ) business for $ 938 million in cash ( the “ inova sale ” ) , as adjusted , and subject to the finalization of

